Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
AT1
vs
S&P/ASX 300
AT1
Over the past 12 months, AT1 has underperformed S&P/ASX 300, delivering a return of -38% compared to S&P/ASX 300's +4% growth.
Stocks Performance
AT1 vs S&P/ASX 300
Performance Gap
AT1 vs S&P/ASX 300
Create a free account · No card needed
Performance By Year
AT1 vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atomo Diagnostics Ltd
Glance View
Atomo Diagnostics makes rapid diagnostic test kits and the components that go into them. Its main business is designing and supplying patented sample collection and testing platforms that help turn a small blood, saliva, or other sample into a clear test result quickly. The company also works with partners to adapt these platforms for specific medical tests. Its customers are usually medical test developers, laboratories, healthcare brands, and distributors that need a simple way to package and run point-of-care tests. Atomo makes money by selling its test devices and related parts, and by earning development and licensing income when partners use its technology in their own diagnostic products. That means it sits in the middle of the diagnostic value chain, not as a hospital or lab, but as a technology supplier to them. What makes the business model different is that Atomo focuses on the disposable hardware and sample-handling piece of testing rather than on one single disease area. Its platform approach lets it support many different test types with the same core device design, which can make it useful to partners that want faster, simpler testing without building their own collection system from scratch.
Create a free account · No card needed